Co-detection of chimeric bcr/abl (target) and β-actin (control) messenger RNA in individual CFU-GM colonies derived from CML patients using the polymerase chain reaction

David Wisniewski, Annabel Strife, Bayard Clarkson

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

In order to quantitate the magnitude of the normal and Philadelphia (Ph′) chromosome-positive(+) progenitor cells for various research and clinical settings/studies, we have applied the highly sensitive polymerase chain reaction (PCR) for examining the cells contained in individual hematopoietic colonies for chimeric bcr/abl mRNA, a specific molecular marker for chronic myelogenous leukemia (CML). Thus, individual 14-day CFU-GM colonies, obtained by growth of bone marrow cells from CML patients were removed from methylcellulose cultures and total RNA from each colony was isolated. First-strand complementary DNAs (cDNA) corresponding to all mRNAs in the sample were obtained by using random hexamers in a reverse transcription (RT) reaction. cDNA then served as the substrate in the PCR. To ensure the integrity of the RNA extracted from each colony, β-actin and bcr/abl cDNA sequences were amplified in the same reaction vessel. Using this method, we have examined the colonies grown from threee CML patients and found that 5 out of 5, 9 out of 9 and 8 out of 9 colonies contained a bcr/abl transcript. This method is simple, highly sensitive and should facilitate studies comparing the expression of various oncogenes in normal and leukemic hematopoietic progenitor cells.

Original languageEnglish
Pages (from-to)867-874
Number of pages8
JournalLeukemia Research
Volume15
Issue number9
DOIs
StatePublished - 1991
Externally publishedYes

Keywords

  • CFU-GM
  • Polymerase chain reaction
  • bcr/abl mRNA
  • chronic myelogenous leukemia
  • gene expression

Fingerprint

Dive into the research topics of 'Co-detection of chimeric bcr/abl (target) and β-actin (control) messenger RNA in individual CFU-GM colonies derived from CML patients using the polymerase chain reaction'. Together they form a unique fingerprint.

Cite this